Measurable residual disease assessment by qPCR in peripheral blood is an informative tool for disease surveillance in childhood acute myeloid leukaemia
- 16 March 2020
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 190 (2), 198-208
- https://doi.org/10.1111/bjh.16560
Abstract
Serial assessments of measurable (or minimal) residual disease (MRD) by qPCR may identify nascent relapse in children with acute myeloid leukaemia (AML) and enable pre‐emptive therapy. We investigated the kinetics and prognostic impact of recurrent fusion transcripts (RUNX1‐RUNX1T1, CBFB‐MYH11, KMT2A‐MLLT3 or KMT2A‐ELL) in 774 post‐induction samples from bone marrow (BM, 347) and peripheral blood (PB, 427) from 75 children with AML. BM MRD persistence during consolidation did not increase the risk of relapse, and MRD at therapy completion did not correlate to outcome (HR = 0·64/MRD log reduction (CI: 0·32–1·26), P = 0·19). In contrast, 8/8 patients with detectable MRD in PB after first consolidation relapsed. Persistence (n = 4) and shifting from negative to positive (n = 10) in PB during follow‐up predicted relapse in 14/14 patients. All 253 PB samples collected during follow‐up from 36 patients in continuous complete remission were MRD negative. In core‐binding factor AML, persistent low‐level MRD positivity in BM during follow‐up was frequent but an increment to above 5 × 10−4 heralded subsequent haematological relapse in 12/12 patients. We demonstrate that MRD monitoring in PB after induction therapy is highly informative and propose an MRD increment above 5 × 10−4 in PB and BM as a definition of molecular relapse since it always leads to haematological relapse.Keywords
Funding Information
- Børnecancerfonden
This publication has 36 references indexed in Scilit:
- Prognostic significance of flow‐cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP‐AML 2002/01 study protocolBritish Journal of Haematology, 2017
- Minimal Residual Disease Monitoring in Acute Myeloid Leukemia (AML) with Translocation t(8;21)(q22;q22): Results of the AML Study Group (AMLSG)Blood, 2016
- Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004Blood, 2013
- Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panelBlood, 2012
- Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004Blood, 2012
- Response-Guided Induction Therapy in Pediatric Acute Myeloid Leukemia With Excellent Remission RateJournal of Clinical Oncology, 2011
- Prognostic Impact of Minimal Residual Disease inCBFB-MYH11–Positive Acute Myeloid LeukemiaJournal of Clinical Oncology, 2010
- Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer programLeukemia, 2003
- Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer ProgramLeukemia, 2003
- Flexible regression models with cubic splinesStatistics in Medicine, 1989